Therapeutic potential of diosmin, a citrus flavonoid against arsenic-induced neurotoxicity via suppression of NOX 4 and its subunits.


Journal

Indian journal of pharmacology
ISSN: 1998-3751
Titre abrégé: Indian J Pharmacol
Pays: India
ID NLM: 7902477

Informations de publication

Date de publication:
Historique:
entrez: 8 6 2021
pubmed: 9 6 2021
medline: 22 2 2022
Statut: ppublish

Résumé

Water contaminated with arsenic affected millions of people worldwide and arsenic exposure is related to various neurological disorders. Hence, the current study was planned to investigate the neuroprotective activity of diosmin (DSN) against arsenic induced neurotoxicity as an attempt to identify therapeutic intervention to combat arsenicism. Sodium arsenite an inducer of neurotoxicity was administered orally (13 mg/kg) and DSN treatment at two selected doses (50 and 100 mg/kg) was done for 21 days. Behavioral and biochemical variations were examined by various parameters. Furthermore, histopathological and immunohistochemistry studies were done with the brain sections. The behavioral studies evidenced that arsenic has suppressed the exploratory behavior and motor coordination in rats and DSN treatment has recovered the behavioral changes to normal. Arsenic administration has also found to induce oxidative stress and DSN co-treatment has ameliorated the oxidative stress markers. Interestingly, depleted levels of neurotransmitters were observed with the arsenic and it was restored back by the DSN treatment. Histopathological alterations like pyknosis of the neuronal cells were identified with arsenic exposure and subsided upon DSN co administration. Immunohistochemical studies have revealed the expression of NOX4 and its gp91 Treatment with DSN showed a beneficial effect in protecting against arsenic-induced neurotoxicity by suppressing the toxicity changes and the antioxidant effect of DSN might be attributed to its ability of suppressing NOX4 and its subunits.

Identifiants

pubmed: 34100397
pii: Indian J Pharmacol_2021_53_2_132_316956
doi: 10.4103/ijp.IJP_837_19
pmc: PMC8265410
doi:

Substances chimiques

Antioxidants 0
Neuroprotective Agents 0
Neurotransmitter Agents 0
Protein Subunits 0
Diosmin 7QM776WJ5N
NADPH Oxidase 4 EC 1.6.3.-
Arsenic N712M78A8G

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

132-142

Déclaration de conflit d'intérêts

None

Références

Behav Brain Res. 2010 Dec 1;213(2):238-45
pubmed: 20457184
J Neurosci Methods. 1990 Feb;31(2):101-7
pubmed: 2319810
Chem Biol Interact. 2017 Aug 1;273:180-189
pubmed: 28625489
PLoS Biol. 2010 Sep 21;8(9):
pubmed: 20877715
Eur J Neurosci. 2013 Mar;37(6):1022-31
pubmed: 23294165
Toxicol Lett. 1990 Dec;54(2-3):345-53
pubmed: 2260129
Br J Pharmacol. 1985 Nov;86(3):729-35
pubmed: 2866006
J Biomed Sci. 2010 Aug 24;17 Suppl 1:S7
pubmed: 20804627
J Vis Exp. 2011 Mar 10;(49):
pubmed: 21445033
J Immunol. 2008 May 1;180(9):6010-7
pubmed: 18424721
Toxicol Lett. 2002 Nov 15;136(1):65-76
pubmed: 12368058
Psychopharmacology (Berl). 1987;92(2):180-5
pubmed: 3110839
Gen Physiol Biophys. 2019 Jul;38(4):315-324
pubmed: 31241043
Free Radic Biol Med. 2011 Jul 15;51(2):257-81
pubmed: 21554949
J Integr Med. 2014 Jan;12(1):35-41
pubmed: 24461593
Prog Neuropsychopharmacol Biol Psychiatry. 2005 Dec;29(8):1214-24
pubmed: 16226365
Curr Protoc Toxicol. 2009;42(431):4.31.1-4.31.6
pubmed: 25419261
Am J Physiol Lung Cell Mol Physiol. 2001 Mar;280(3):L442-9
pubmed: 11159027
Drug Chem Toxicol. 2009;32(2):93-102
pubmed: 19514944
Neuroscience. 2014 May 30;268:318-27
pubmed: 24680937
Alcohol. 2013 Mar;47(2):131-9
pubmed: 23419394
Toxicol Appl Pharmacol. 2001 Jul 15;174(2):130-8
pubmed: 11446828
Psychopharmacology (Berl). 1995 Sep;121(1):66-72
pubmed: 8539342
Clin Chim Acta. 2003 Mar;329(1-2):23-38
pubmed: 12589963
J Neurosci Res. 1976;2(3):193-202
pubmed: 1033296
Biomed Res Int. 2015;2015:159015
pubmed: 26114099
Chem Biol Interact. 2008 Nov 25;176(2-3):188-95
pubmed: 18674524
Saudi Pharm J. 2013 Apr;21(2):143-52
pubmed: 24936134
J Biol Chem. 2005 Feb 4;280(5):3875-84
pubmed: 15492012
J Neurosci. 1990 Feb;10(2):588-602
pubmed: 2137532
Molecules. 2013 Mar 01;18(3):2821-39
pubmed: 23455672
Int J Epidemiol. 1998 Oct;27(5):871-7
pubmed: 9839746
Biochem Pharmacol. 1974 Sep 1;23(17):2437-46
pubmed: 4429570
J Toxicol Clin Toxicol. 2001;39(7):675-82
pubmed: 11778665

Auteurs

Rupasree Peruru (R)

Department of Pharmacology, Institute of Pharmaceutical Technology, Sri Padmavati Mahila Visvavidyalayam (Women's University), Tirupati, Andhra Pradesh, India.

Sujatha Dodoala (S)

Department of Pharmacology, Institute of Pharmaceutical Technology, Sri Padmavati Mahila Visvavidyalayam (Women's University), Tirupati, Andhra Pradesh, India.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH